Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
August 08, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
July 13, 2023 23:15 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
July 13, 2023 16:03 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Proposed Public Offering of Common Stock

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...
July 13, 2023 16:01 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...
July 06, 2023 08:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s...
May 31, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
May 09, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
May 08, 2023 09:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a...
May 01, 2023 16:00 ET | Source: Caribou Biosciences, Inc.

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...